Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sara Costi

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Psychiatry|January 5, 2021
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress DisorderAdriana Feder, Sara Costi, Sarah B Rutter, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress DisorderAdriana Feder, Sara Costi, Sarah B Rutter, et al.
Translational Psychiatry|November 6, 2021
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedoniaSara Costi, Laurel S Morris, Abigail Collins, et al.
Molecular Psychiatry|November 3, 2018
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorderAaron Tan, Sara Costi, Laurel S Morris, et al.
The Journal of Clinical Psychiatry|April 11, 2025
Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label TrialAdriana Feder, Oneysha Brown, Sarah B Rutter, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
The American Journal of Psychiatry|March 3, 2021
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled TrialSara Costi, Laurel S Morris, Katherine A Kirkwood, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Research Square|February 13, 2023
Peripheral immune-derived matrix metalloproteinase promotes stress susceptibilityFlurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, et al.
Nature|February 7, 2024
Circulating myeloid-derived MMP8 in stress susceptibility and depressionFlurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
The American Journal of Psychiatry|January 5, 2021
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress DisorderAdriana Feder, Sara Costi, Sarah B Rutter, et al.
Focus (American Psychiatric Publishing)|July 5, 2023
A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress DisorderAdriana Feder, Sara Costi, Sarah B Rutter, et al.
Translational Psychiatry|November 6, 2021
Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedoniaSara Costi, Laurel S Morris, Abigail Collins, et al.
Molecular Psychiatry|November 3, 2018
Effects of the KCNQ channel opener ezogabine on functional connectivity of the ventral striatum and clinical symptoms in patients with major depressive disorderAaron Tan, Sara Costi, Laurel S Morris, et al.
The Journal of Clinical Psychiatry|April 11, 2025
Combining Ketamine Infusions and Written Exposure Therapy for Chronic PTSD: An Open-Label TrialAdriana Feder, Oneysha Brown, Sarah B Rutter, et al.
JAMA Network Open|June 25, 2024
Ketamine vs Electroconvulsive Therapy for Treatment-Resistant Depression: A Secondary Analysis of a Randomized Clinical TrialManish Kumar Jha, Samuel T Wilkinson, Kamini Krishnan, et al.
The American Journal of Psychiatry|March 3, 2021
Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled TrialSara Costi, Laurel S Morris, Katherine A Kirkwood, et al.
The New England Journal of Medicine|May 24, 2023
Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major DepressionAmit Anand, Sanjay J Mathew, Gerard Sanacora, et al.
Research Square|February 13, 2023
Peripheral immune-derived matrix metalloproteinase promotes stress susceptibilityFlurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, et al.
Nature|February 7, 2024
Circulating myeloid-derived MMP8 in stress susceptibility and depressionFlurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, et al.
Pageof 3